Constellation Brands, Inc. (STZ) Stock Analysis
Is STZ a good investment?
Constellation Brands, Inc. (STZ) has a Plutrex AI rating of 42.0/100 as of October 09, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: Best-in-class profitability: operating margin 32.47% is 72.8% above industry average (18.79%) and net margin 20.90% is 148.8% above peers (8.40%), demonstrating a deeply entrenched, high-quality business model with durable competitive moat in branded beverage alcohol. Main concern: Catastrophic growth deceleration: 5-year forward EPS CAGR of 3.1% vs. industry average 11.53% (72.8% below peers), compounded by YoY EPS already contracting -4.7% and zero analyst consensus on next-year EPS — the growth engine has stalled and the PEG of 3.54x (67.7% above industry 2.11x) means investors are massively overpaying for available growth.
Investment Summary
Constellation Brands (STZ) at $123.63 is a structurally excellent but growth-impaired business facing a fundamental valuation trap. The company posts world-class profitability — operating margin of 32.47% (vs. industry 18.79%), ROE of 23.92% (vs. industry 10.62%), and net margin of 20.90% (vs. industry 8.40%) — but these strengths are being systematically undermined by a catastrophic growth deceleration. Historical EPS growth of 25.3% has collapsed to a 5-year forward projection of just 3.1%, well below both inflation and peer average of 11.53%. YoY EPS is already contracting at -4.7%. The PEG ratio of 3.54 (vs. industry 2.11) confirms that despite a headline P/E of just 11.09x, investors are dramatically overpaying for available growth. News is mixed: Q2 beat estimates and FY2027 EPS guidance of $11.20-$11.90 was reiterated, but multiple analysts cut forecasts post-results, and core brands Corona and Modelo are shrinking while the company pivots to smaller brands Pacifico and Victoria. Debt-to-equity of 1.06x (vs. industry 0.775x) and only $98.5M cash against $714.8M FCF leave limited strategic flexibility. Analyst consensus target of $147.92 implies 19.6% upside, but the forward growth trajectory doesn't support chasing that target aggressively.
Key Strengths
- Best-in-class profitability: operating margin 32.47% is 72.8% above industry average (18.79%) and net margin 20.90% is 148.8% above peers (8.40%), demonstrating a deeply entrenched, high-quality business model with durable competitive moat in branded beverage alcohol
- Strong free cash flow of $714.8M annually provides meaningful debt servicing capacity and financial resilience; Q2 2025 earnings beat estimates with FY2027 EPS guidance of $11.20-$11.90 reiterated, confirming management's near-term confidence
- ROE of 23.92% — 125.2% above the industry average of 10.62% — confirms exceptional capital efficiency; combined with a PE of 11.09x (35.9% discount to industry), the absolute valuation offers a floor for value-oriented investors if growth concerns prove overstated
Key Concerns
- Catastrophic growth deceleration: 5-year forward EPS CAGR of 3.1% vs. industry average 11.53% (72.8% below peers), compounded by YoY EPS already contracting -4.7% and zero analyst consensus on next-year EPS — the growth engine has stalled and the PEG of 3.54x (67.7% above industry 2.11x) means investors are massively overpaying for available growth
- Core brand erosion: headline 'Corona and Modelo Are Shrinking While Pacifico and Victoria Are Booming' signals that the two brands that built STZ's premium valuation are losing volume, and multiple analysts slashed forecasts following Q2 results despite the beat — suggesting the structural headwinds are worse than reported earnings indicate
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
STZ's financial profile is deeply bifurcated. Profitability is exceptional: gross margin 50.78% (industry avg 48.36%), operating margin 32.47% (industry 18.79% — a 72.8% premium), net margin 20.90% (industry 8.40% — a 148.8% premium), and ROE 23.92% (industry 10.62% — a 125.2% premium). Free cash flow of $714.8M is robust and the primary financial health anchor. However, the balance sheet is a liability: D/E of 1.06x vs. industry 0.775x, cash of only $98.5M (thin vs. the debt load), and operating-to-net margin compression of 11.6 percentage points signals heavy interest burden. Growth is the existential concern: 5-year EPS CAGR of 3.1% vs. industry 11.53%, YoY EPS -4.7%, and next-year EPS estimate is N/A (no consensus), creating a near-complete lack of forward earnings visibility. Revenue growth of 6.1% is in line with peers but cannot compensate for earnings conversion deterioration. Valuation: P/E of 11.09x (35.9% discount to industry 17.31x) looks cheap superficially, but PEG of 3.54x (67.7% premium to industry 2.11x) exposes the growth-adjusted overvaluation. FCF-based intrinsic value at $714.8M / (9% - 3.1%) ≈ $12.1B enterprise value implies limited equity margin of safety at current prices after netting out the leveraged debt load.
News Sentiment
Constellation Brands is navigating one of the trickiest moments in its corporate history — its empire-building beer brands are hitting a wall just as smaller alternatives pick up speed. The maker of Corona and Modelo reported a solid second quarter, beating Wall Street's estimates on both profit and sales, and management stood by its full-year earnings guidance of $11.20 to $11.90 per share. That's the good news. But the story underneath those numbers is more complicated. In a revealing headline — 'Corona and Modelo Are Shrinking While Pacifico and Victoria Are Booming' — the company's two biggest cash cows are losing drinkers. That's a significant problem for a company whose premium valuation was built on those very brands. Meanwhile, the company is 'getting creative to bring back beer drinkers' as overall demand softens, signaling the easy growth days may be over. Wall Street isn't buying the optimism fully — multiple analysts slashed their price targets following Q2 results even as the company beat estimates, suggesting the beat wasn't strong enough to offset concern about the direction of travel. The silver lining? The company's cash flow remains powerful, inventory levels have improved, and the management team is adapting its brand portfolio. For patient investors willing to wait for a better entry price, STZ's fundamental quality remains intact — but the growth story needs a serious rewrite before this stock deserves a full vote of confidence.
Risk Assessment
PRIMARY RISK: Growth deceleration is structural rather than cyclical. If 5-year EPS CAGR remains at 3.1% and core brands (Corona, Modelo) continue losing volume, the PE of 11.09x may compress further toward 8-9x — implying 20-30% downside from current levels to the $85-$100 range. SECONDARY RISK: Leverage amplifies downside — D/E of 1.06x and only $98.5M cash means any revenue softness flows directly into credit metrics. TERTIARY RISK: Analyst forecast cuts post-Q2 (headline: 'These Analysts Slash Their Forecasts On Constellation Brands Following Q2 Results') suggest the beat quality was poor with guidance caution embedded. MITIGATION: The $714.8M FCF provides a strong floor — even in a bear case, the company services debt comfortably. Entry below $115 provides a margin of safety by pricing in continued PE compression to ~9x on $11.50 forward EPS mid-range. Stop at $98 limits loss to approximately 12% from entry midpoint. Position capped at 2% given uncertainty.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is STZ a halal stock?
No, Constellation Brands, Inc. (STZ) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for STZ?
Constellation Brands, Inc. (STZ) has a Plutrex AI rating of 42.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is STZ a good investment?
According to Plutrex AI, STZ has a Sell rating (42.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in STZ?
US stocks like STZ can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in STZ?
Plutrex AI identifies the main risks for STZ by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.